SEC Form 4 · accession 0001140361-18-028125
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Fuhrman
Director
Period of report
Jun 8, 2018
Accepted (ET)
Jun 11, 2018 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2018 | M | 2,625 | $11.35 | A | 2,625 | D | |
| Common StockF1,F2 | Jun 8, 2018 | S | 2,625 | $178.0711 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F3 | $11.35 | Jun 8, 2018 | M | 2,625 | D | — | Jan 11, 2025 | Common Stock | 2,625 | 13,000 | D |
Explanation of responses
- F1Represents the aggregate of sales effected on the same day at different prices.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $177.931 to $178.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3The stock option is fully vested and immediately exercisable.